

Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 16, 1989.

A. Federal Reserve Bank of Cleveland (John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Society Corporation*, Cleveland, Ohio; to engage *de novo* through its subsidiary, Society National Trust Company, in organization, Naples, Florida, in acting as investment or financial advisor pursuant to § 225.25(b)(4) of the Board's Regulation Y. These activities will be conducted in the Collier County and the State of Florida.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Perham State Bancshares*, Perham, Minnesota; to engage *de novo* in making loans to its common stockholders pursuant to § 225.25(b)(1) of the Board's Regulation Y. These activities will be conducted in Perham, Minnesota.

Board of Governors of the Federal Reserve System, January 19, 1989.

Jennifer J. Johnson,

Associate Secretary of the Board.

[FR Doc. 89-1834 Filed 1-25-89; 8:45 am]

BILLING CODE 6210-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Family Support Administration

Reconsideration of the Disapproval of Tennessee's Proposed Title IV-A State Plan Amendment

AGENCY: Department of Health and Human Services, FSA.

ACTION: Notice of hearing.

SUMMARY: The date of the hearing to reconsider the disapproval of Tennessee's State Plan Submittal No. ES-AP-88-2 noticed in 53 FR 47767, November 25, 1988, has been changed.

DATES: The hearing is rescheduled for 10:00 a.m. on February 17, 1989.

ADDRESSES: The hearing will be held in Room 905, 101 Marietta Tower, corner of Marietta and Spring Streets, Atlanta, Georgia.

FOR FURTHER INFORMATION CONTACT: Thomas D. Horvath, Senior Attorney, Departmental Appeals Board, Department of Health and Human Services, Room 451-F, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201, Telephone Number (202) 475-0013.

Alexander G. Teitz,
Presiding Officer.

Date: January 19, 1989.

[FR Doc. 89-1785 Filed 1-25-89; 8:45 am]

BILLING CODE 4150-04-M

Food and Drug Administration

Countrymark, Inc.; Withdrawal of Approval of NADA's

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of two new animal drug applications (NADA's) held by Countrymark, Inc. The NADA's provide for the use of (1) pyrantel tartrate Type A medicated articles for making Type C medicated swine feeds, and (2) tylosin/sulfamethazine Type A medicated articles for making Type C medicated swine feeds. The firm requested the withdrawal of approval.

FOR FURTHER INFORMATION CONTACT:

Mohammad I. Sharar, Center for Veterinary Medicine (HFV-216), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3183.

SUPPLEMENTARY INFORMATION:

Countrymark, Inc. (formerly Ohio Farmers Grain and Supply Association), 4565 Columbus Pike, Rt. 23 North, Delaware, OH 43015-1206, is the sponsor of NADA's 138-940 and 138-343 which were originally approved October 18, 1985 (50 FR 42156) and June 18, 1985 (50 FR 25218), respectively. NADA 138-940 provides for the use of Type A medicated articles containing 9.6 and 19.2 grams of pyrantel tartrate per pound for making Type C medicated swine feeds to be used as anthelmintics, and NADA 138-343 provides for the use of Type A medicated articles containing four concentrations of equal amounts of tylosin and sulfamethazine for making Type C medicated swine feeds to be used in accordance with 21 CFR 558.630(f)(2)(ii).

In letters dated June 2, 1988, the sponsor requested the withdrawal of approval of the NADA's because the products are no longer marketed.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(e), 82 Stat. 345-347 (21 U.S.C. 360b(e))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA's 138-940 and 138-343 and all supplements thereto is hereby withdrawn, effective February 6, 1989.

In a final rule published elsewhere in this issue of the *Federal Register*, FDA is removing 21 CFR 558.485(a)(24) and reserving it for future use, and the firm's drug labeler code No. "026439" from 21 CFR 558.630(b)(10).

Dated: January 18, 1989.

Gerald B. Guest,

Director, Center for Veterinary Medicine.

[FR Doc. 89-1820 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

Food and Drug Administration

The Dow Chemical Co.; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing

approval of a new animal drug application (NADA) held by The Dow Chemical Co. The NADA provides for use of a Type A medicated article containing zoalene and roxarsone for making Type C medicated chicken feeds. The firm requested withdrawal of approval.

EFFECTIVE DATE: February 6, 1989.

FOR FURTHER INFORMATION CONTACT:

Mohammad I. Sharar, Center for Veterinary Medicine (HFV-216), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-3183.

SUPPLEMENTARY INFORMATION: The Dow Chemical Co., P.O. Box 1706, Midland, MI 48640, is the sponsor of NADA 36-682 which was originally approved by letter of August 28, 1967. The NADA provides for use of the type the Type A medicated article Zoamix® N which contains 25 percent zoalene and 10 percent roxarsone in making Type C medicated chicken feeds. The feeds are used as an aid for the prevention and control of caecal and intestinal coccidiosis and as an aid in stimulating growth, increasing feed efficiency, and for improving pigmentation.

In a letter dated May 16, 1988, the sponsor requested withdrawal of approval of the NADA and waived opportunity for hearing because the product is no longer being marketed.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(e), 82 Stat. 345-347 (21 U.S.C. 360b(e))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA 36-682 and all supplements thereto is hereby withdrawn, effective February 6, 1989.

Dated: Jan 18, 1989.

Gerald B. Guest,

Director, Center for Veterinary Medicine.

[FR Doc. 89-1716 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 81D-0319]

Collection of Platelets, Pheresis; Availability of Revised Guideline

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a revised guideline prepared by the Center for Biologics Evaluation and Research for the

collection of Platelets. Pheresis prepared by automated procedures using a currently approved instrument. The guideline is intended for use by blood collecting facilities that prepare platelets by this method.

ADDRESSES: The guideline may be seen at and comments submitted to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857. Requests for a copy of the revised guideline to the Biologics Information Staff (HFB-205), Building 29, Room B-16, 8800 Rockville Pike, Bethesda, MD 20892, 301-496-9508.

FOR FURTHER INFORMATION CONTACT:

Joseph Fratantoni, Center for Biologics Evaluation and Research (HFB-480), Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, 301-496-2577.

SUPPLEMENTARY INFORMATION: In the Federal Register of October 27, 1981 (46 FR 52430), FDA announced the availability of a guideline for the collection of Platelets, Pheresis prepared by mechanical pheresis using a currently approved instrument. Platelets, Pheresis is a licensed biological product that may be prepared using automated equipment in an approved blood banking facility. FDA made the guideline available to recommend criteria for donor safety and to help ensure that final platelet products were safe and effective. In the Federal Register of April 2, 1984 (49 FR 13079), FDA announced the availability of a draft revised guideline intended to replace the original guideline made available in 1981. The draft revised guideline differed from the original guideline in several ways, including a revised standard for Platelets, Pheresis, a provision for donation of platelets for a specific recipient, and removal of some recommended platelet testing and processing procedures during donation periods.

In the 1984 notice, FDA also announced a 2-day public workshop to discuss issues concerning platelets. Public comments received on the draft revised guideline were discussed during the public workshop held on May 22 and 23, 1984. The draft revised guideline has been revised further as a result of comments received. Since 1984 FDA has approved new instrumentation and separation techniques, and has implemented additional testing for assuring the safety of blood products. These changes are reflected in the revised guideline.

In addition, the current revised guideline differs from the April 1984 draft revised guideline with respect to recommendations such as the donor

deferral time interval after aspirin ingestion, an increase in the maximum number of platelet collections from a donor in any 1 year, and revised labeling.

FDA is making available the revised guideline under 21 CFR 10.90(b), which provides for the use of guidelines to outline procedures or standards of general applicability that are acceptable to FDA for a subject matter that falls within the laws administered by FDA. Although guidelines are not a legal requirement, a person may be assured that in following an agency guideline the procedures followed and standards used will be acceptable to FDA. A person may also choose to use alternative procedures or standards for which there is scientific rationale even though they are not provided for in a guideline. A person who chooses to use procedures or standards different from procedures or standards in a guideline may discuss the matter further with the agency to prevent an expenditure of resources for work that FDA may later determine to be unacceptable.

Copies of the revised guideline have been distributed to blood bank establishments and plasmapheresis centers that have pending or approved license applications to prepare Platelets, Pheresis using pheresis instruments for which the Center for Biologics Evaluation and Research has acceptable data.

Requests for a copy of the revised guideline should be sent to the Biologics Information Staff (address above).

Interested persons may submit to the Dockets Management Branch written comments on the revised guideline. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

Dated: January 18, 1989.

John M. Taylor

Associate Commissioner for Regulatory Affairs.

[FR Doc. 89-1715 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 88F-0442]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of *N*-methyl-*N*-(1-oxo-9-octadecenyl)glycine as a corrosion inhibitor for lubricants with incidental food contact.

FOR FURTHER INFORMATION CONTACT: Andrew D. Laumbach, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4124) has been filed by Ciba-Geigy Corp., Three Skyline Dr., Hawthorne, NY 10532, proposing that § 178.3570 *Lubricants with incidental food contact* (21 CFR 178.3570) be amended to provide for the safe use of *N*-methyl-*N*-(1-oxo-9-octadecenyl)glycine as a corrosion inhibitor for lubricants with the incidental food contact.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c).

Dated: January 13, 1989.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89-1713 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 88F-0426]

Huels AG; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Huels AG has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 3-aminomethyl-3,5,5-trimethylcyclohexylamine as a cross-linking agent for use in epoxy resins complying with the indirect food additive regulations.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF-335), Food and

Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4118) has been filed by Huels AG, P.O. Box 1320, D-4370 Marl, Federal Republic of Germany, proposing that § 175.300 *Resinous and polymeric coatings* (21 CFR 175.300) be amended to provide for the safe use of 3-aminomethyl-3,5,5-trimethylcyclohexylamine as a cross-linking agent for use in epoxy resins complying with § 175.300(b)(3)(viii).

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c).

Dated: January 13, 1989.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89-1714 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 85F-0082]

Ecolab, Inc.; Amended Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is amending the filing notice for a food additive petition filed by Economics Laboratory, Inc. (now Ecolab, Inc.), to provide for the safe use of decanoic acid, octanoic acid, a mixture of 1-octanesulfonic acid and 1-octanesulfonic-2-sulfonic acid, and the condensate of four moles of poly(oxyethylene)poly(oxypropylene) block copolymers with one mole of ethylenediamine as components of sanitizing solutions to be used on food-processing equipment and other food-contact articles. This notice makes clear that the sanitizing solution also contains lactic acid, phosphoric acid, and FD&C Yellow No. 5, and that the mixture of 1-octanesulfonic acid and 1-octanesulfonic-2-sulfonic acid also contains 1,2-octanedisulfonic acid.

FOR FURTHER INFORMATION CONTACT: Richard H. White, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St.

SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: In a notice published in the *Federal Register* of March 8, 1985 (46 FR 9521), FDA announced that a petition (FAP 5H3842) had been filed by Economics Laboratory, Inc., St. Paul, MN 55102 (the name and address of the company have been changed to Ecolab, Inc., Ecolab Center, St. Paul, MN 55102), proposing that the food additive regulations be amended to provide for the safe use of decanoic acid, octanoic acid, a mixture of 1-octanesulfonic acid and 1-octanesulfonic-2-sulfonic acid, (OSA mixture), and the condensate of four moles of poly(oxyethylene)poly(oxypropylene) block copolymers with one mole of ethylenediamine as components of sanitizing solutions to be used on food processing equipment and other food-contact articles. Subsequently, Ecolab, Inc., amended the petition and indicated the presence of 1,2-octanedisulfonic acid in the OSA mixture.

This notice makes clear that this ingredient is in the sanitizing solution and that this solution also contains FD&C Yellow No. 5, lactic acid, and phosphoric acid, components which were also not listed in the original notice of filing.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding may be seen in the Dockets Management Branch, Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD between 9 a.m. and 4 p.m., Monday through Friday. Under FDA's regulations implementing the National Environmental Policy Act (21 CFR Part 25), an action of this type would require an environmental assessment under 21 CFR 25.31a(a).

Dated: January 13, 1989.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89-1819 Filed 1-25-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 88G-0388]

Fuji Oil Co., Ltd.; Filing of Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration.

ACTION: Notice.